Okamoto Industries (5122) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
21 Jul, 2026Executive summary
Net sales rose 4.6% year-over-year to ¥83,046 million for the nine months ended December 31, 2024.
Operating income declined 11.3% year-over-year to ¥7,112 million, while ordinary income fell 11.0% to ¥8,443 million.
Profit attributable to owners of parent dropped 27.5% year-over-year to ¥5,079 million.
Comprehensive income decreased to ¥5,408 million from ¥11,943 million in the prior year period.
Financial highlights
Gross profit was ¥18,500 million, nearly flat year-over-year.
Total assets increased to ¥145,248 million as of December 31, 2024, up from ¥143,858 million at March 31, 2024.
Equity ratio improved to 63.1% from 61.6% at the previous fiscal year-end.
Net income per share was ¥291.41, down from ¥398.47 year-over-year.
Outlook and guidance
Full-year net sales forecast is ¥111,000 million, up 4.6% year-over-year.
Operating income is projected to decrease 7.9% to ¥9,250 million, and profit attributable to owners of parent is expected to decline 9.3% to ¥6,700 million.
Dividend forecast for FY2025 is ¥135 per share, unchanged from the previous forecast.
Latest events from Okamoto Industries
- Net sales grew 6.9% year-over-year, with full acquisition of RIKEN CORUNDUM completed.5122
Q2 202521 Jul 2026 - Sales and operating profit rose, but net profit fell on higher impairment losses.5122
Q1 202521 Jul 2026 - Net sales rose 2.8% year-over-year, but profit and operating income declined amid flat FY2026 outlook.5122
Q4 202521 Jul 2026 - Net sales rose, but profits declined sharply year-over-year; guidance and dividends unchanged.5122
Q1 202621 Jul 2026 - Profits fell sharply on weaker demand and higher costs, but dividends and buybacks continue.5122
Q2 202621 Jul 2026 - Profits fell on currency and cost pressures, but full-year guidance remains optimistic.5122
Q3 202621 Jul 2026 - Sales and profits fell sharply, with only modest recovery forecast amid ongoing risks.5122
Q4 202621 Jul 2026